SCHEMBL6029734

SCHEMBL6029734

CCN(CC)CCOc1cc2ncnc(Oc3ccc4[nH]c(C)cc4c3)c2cc1OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 1/20 0.51
▸ KDR P35968 12/20 0.49
▸ EGFR P00533 6/20 0.49
▸ RET P07949 3/20 0.49
▸ PLK4 O00444 1/20 0.49
▸ GAK O14976 1/20 0.49
▸ EPHB6 O15197 1/20 0.49
▸ RIPK2 O43353 1/20 0.49
▸ ERN1 O75460 1/20 0.49
▸ STK10 O94804 1/20 0.49
▸ MAP4K4 O95819 1/20 0.49
▸ CHEK2 O96017 1/20 0.49
▸ ABL1 P00519 1/20 0.49
▸ ERBB2 P04626 1/20 0.49
▸ LCK P06239 1/20 0.49
▸ FYN P06241 1/20 0.49
▸ CSF1R P07333 1/20 0.49
▸ YES1 P07947 1/20 0.49
▸ LYN P07948 1/20 0.49
▸ MET P08581 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6032099 0.91 KDM1A (0.52) KDM1AKDREGFRRETPLK4
SCHEMBL6030818 0.89 KDM1A (0.55) KDM1AKDREGFRRETPLK4
SCHEMBL6030922 0.88 KDR (0.52) KDM1AKDREGFRRETPLK4
SCHEMBL664052 0.87 KDM1A (0.54) KDM1AKDREGFRRETPLK4
SCHEMBL4371598 0.87 KDR (0.54) KDM1AKDREGFRRETPLK4
SCHEMBL6029655 0.86 KDM1A (0.52) KDM1AKDREGFRRETLCK
SCHEMBL4375103 0.86 KDM1A (0.48) KDM1AKDREGFRRETPLK4
SCHEMBL6031295 0.86 KDR (0.47) KDM1AKDREGFRRETPLK4
SCHEMBL6031625 0.85 KDR (0.44) KDM1AKDREGFRRETPLK4
SCHEMBL4375025 0.85 KDR (0.48) KDM1AKDREGFRRETPLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7074800-B1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2006-07-11 — — US claimed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 — — EP claimed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 — — WO claimed
US-8492560-B2 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2013-07-23 — — US disclosed
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors STOKES ELAINE S E (GB) 2012-08-02 — — US disclosed
US-7074800-B1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2006-07-11 — — US disclosed
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB 2006-01-05 — — US disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 — — EP disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors VEGFA, FLT1, KDR KDM1A 2417/4885KDR 3/4885EGFR 500/4885
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors FLT4, NOS3, FLT1 KDM1A 2501/4885KDR 4/4885EGFR 549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback